Clinical Pharmacogenomics: Translating Genetic Variation into Individualized Drug Therapy

Kalyani R

doi:10.37022/baddt.v1i2.966

R. Kalyani Student. Avanthi Institute of Pharmaceutical Sciences , Vizianagaram.

DOI https://doi.org/10.37022/baddt.v1i2.966

Abstract

Clinical pharmacogenomics (PGx) is an emerging component of precision medicine that examines how inherited genetic variation influences an individual's response to medicines. Genetic differences affecting drug-metabolizing enzymes, transporters, receptors, immune pathways and therapeutic targets can contribute to interindividual variability in drug efficacy, toxicity and pharmacokinetics. Integration of pharmacogenomic information into clinical practice can therefore support selection of appropriate medicines, individualized dosing and prevention of avoidable adverse drug reactions. Important gene–drug associations include CYP2C19–clopidogrel, CYP2D6–codeine and antidepressants, CYP2C9/VKORC1–warfarin, TPMT/NUDT15–thiopurines, DPYD–fluoropyrimidines and HLA-B*57:01–abacavir. Clinical implementation is supported by evidence-based resources and guidelines developed by organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the Dutch Pharmacogenetics Working Group (DPWG), PharmGKB and regulatory agencies. However, challenges involving test accessibility, cost, interpretation, healthcare professional education, electronic health record integration, reimbursement, ethical considerations and population diversity continue to limit widespread implementation. Recent developments in pre-emptive panel testing, clinical decision-support systems and standardized genotype-to-phenotype interpretation are facilitating broader integration of PGx into healthcare. This review discusses the principles, clinical applications, implementation strategies, benefits and limitations of clinical pharmacogenomics and highlights its potential role in individualized and safer pharmacotherapy.

Keywords: Clinical pharmacogenomics, pharmacogenetics, precision medicine, personalized medicine, pharmacogenomic testing, adverse drug reactions, genotype-guided therapy, pharmacogenomic biomarkers

References

1. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023;24:350–362.
2. U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. FDA; updated 2025.
3. Gant Kanegusuku AL, Chan CW, O'Donnell PH, Yeo KTJ. Implementation of pharmacogenomics testing for precision medicine. Crit Rev Clin Lab Sci. 2024;61(2):89–106.
4. Mosch R, van der Lee M, Guchelaar HJ, Swen JJ. Pharmacogenetic panel testing: a review of current practice and potential for clinical implementation. Annu Rev PharmacolToxicol. 2025;65:91–109.
5. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2C19 and CYP2D6 genotype-to-phenotype translation for clinical pharmacogenomics. ClinPharmacolTher. 2020;107:124–132.
6. Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1 and COMT genotype and select opioid therapy. ClinPharmacolTher. 2021;110:888–896.
7. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium guideline for pharmacogenetics-guided warfarin dosing: 2017 update. ClinPharmacolTher. 2017;102:397–404.
8. Maillard M, Schwab M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update. ClinPharmacolTher. 2026;119(4):916–927.
9. Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. ClinPharmacolTher. 2018;103:210–216.
10. Mosch R, van der Lee M, Guchelaar HJ, Swen JJ. Pharmacogenetic panel testing: a review of current practice and potential for clinical implementation. Annu Rev PharmacolToxicol. 2025;65:91–109.
11. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium guideline development process. Curr Drug Metab. 2014;15(2):209–217.
12. Saito Y, Ozawa S, Kurose K, et al. Pharmacogenomics guidelines: current status and future development. ClinExpPharmacol Physiol. 2019;46:1001–1012.
13. Hall BT, et al. Implementing pharmacogenomics clinical decision support: a comprehensive tutorial on how to integrate the Epic Genomics Module. ClinPharmacolTher. 2025;117(6):1670–1681.
14. Luczak T, Brown SJ, Armbruster D, et al. Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs. Pharmacogenomics. 2021;22(6):345–364.
15. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the CPIC and DPWG. ClinTransl Sci. 2020;13:116–124.
16. Smith DM, Douglas MP, Aquilante CL, et al. Progress in pharmacogenomics implementation in the United States: barrier erosion and remaining challenges. ClinPharmacolTher. 2025;118(4):778–789.
17. Wu A, Raack EJ, Ross CDJ, Carleton BC. Implementation and evaluation strategies for pharmacogenetic testing in hospital settings: a scoping review. Ther Drug Monit. 2025;47(2):211–247.
18. FDA. Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling. U.S. Food and Drug Administration.
19. Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J PharmacolExpTher. 2017;363:183-191.
20. Gawronski BE, Fofanova I, Miranda AM, et al. Implementation of clinical pharmacogenetic testing in medically underserved patients: a narrative review. Pharmacogenomics. 2025;26(3-4):107-119.